sintilimab,IBI939
innovent biologics,eli lilly
['nsclc', 'sintilimab', 'sclc', 'innovent']
dcbn news: innovent updates phase 1b data of ibi939 (anti-tigit monoclonal antibody) combined with sintilimab in previously untreated pd-l1-selected nsclc at the 2023 asco annual meeting: rockville, md. and ... #biotech #news 
Life science news and jobs from Washington DC, Maryland and Virginia. Part of @BiotechNetworks, connecting #biotech since 2008.